Clinical trials: Ovarian Cancer, Epithelial
Breast Cancer, Ovarian Cancer
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Background: Carboplatin is approved by the Food and Drug Administration to treat cancer. AZD2281 is an experimental drug in a class of agents called PARP inhibitors.
- Trial name
- NCT01445418
- Testing
- AZ2281 + Carboplatin
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Clinical Marker
The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. PARP inhibitors(PARPi) are an important progress in EOC treatment.
- Conditions
- Ovarian Cancer, Clinical Marker, PARP Inhibitor
- Trial name
- ROMP (NCT04582552)
- Testing
- PARP inhibitors
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xiaoxiang Chen
Neoplasm Malignant, Breast Cancer
Shorter Scalp Cooling Time in Paclitaxel
Chemotherapy-induced alopecia (CIA) is one of the most distressing side effects for patients. Scalp cooling can prevent or minimise CIA in approximately half of all patients, depending on many factors, e.g.
- Conditions
- Neoplasm Malignant, Breast Cancer, Ovarian Cancer
- Trial name
- COP (NCT03266185)
- Testing
- Shorter PICT
- Where
- Netherlands
- Volunteers
- 91 people
- Sponsor
- Leiden University Medical Center
Cancer
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation.
- Trial name
- NCT00003883
- Testing
- fluconazole, itraconazole
- Where
- 2 sites in United States
- Volunteers
- 578 people
- Sponsor
- Fred Hutchinson Cancer Center
Ovarian Cancer
Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer
The purpose of this study is to evaluate whether or not the addition of Herceptin may be of benefit to a standard regimen of carboplatin-paclitaxel.
- Trial name
- NCT00189579
- Testing
- Herceptin
- Where
- France
- Volunteers
- 45 people
- Sponsor
- ARCAGY/ GINECO GROUP
Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
This phase I trial is studying the side effects and best dose of polyglutamate paclitaxel when given together with carboplatin in treating patients with ovarian epithelial, peritoneal, or fallopian tube cancer.
- Conditions
- Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT00060359
- Testing
- Carboplatin, Paclitaxel Poliglumex, Pharmacological Study
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Neoplasms
Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.
The purpose of this study is to determine whether T900607-sodium is effective and safe in treating ovarian cancer.
- Trial name
- NCT00043446
- Testing
- intravenous T900607-sodium
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tularik
Platinum Sensitive Relapsed Ovarian Cancer
Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers
Weekly carboplatin and taxotere will be tolerable and effective as second line treatment of platinum-sensitive ( >6 month treatment free interval) relapsed ovarian cancer Primary efficacy parameter will be response rate (CR and…
- Trial name
- NCT00247988
- Testing
- Weekly Taxotere with weekly carboplatin
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- University of Saskatchewan
Breast Reconstruction, Breast Cancer
Evaluation of Well Being and Patient Reported Outcomes After Robotic Single-port Nipple Sparing Mastectomy and Implant Reconstruction
This study is being carried out to better understand how different types of mastectomy surgeries affect women's recovery, satisfaction, and overall well-being after breast cancer surgery and reconstruction.
- Conditions
- Breast Reconstruction, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Robotic Surgery
- Trial name
- Reborn-i (NCT07236359)
- Testing
- Intervention, Standard open nipple sparing mastectomy with immediate implant-based reconstruction
- Volunteers
- 108 people
- Sponsor
- Beaumont Hospital
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03907527
- Testing
- PRGN-3005 UltraCAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Precigen, Inc
Ovarian Cancer
Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study
This is an observational phase IV study evaluating Niraparib as maintenance treatment in patients with platinum sensitive, platinum responsive, recurrent ovarian cancer in a real life setting.
- Trial name
- MITO 34 (NCT04617470)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ovarian Cancer
Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients
At present, the treatment of recurrent ovarian cancer after PARP inhibitor therapy is quite challenging, and there is no research on the application of hyperthermic intraperitoneal chemotherapy(HIPEC) for the above-mentioned…
- Trial name
- NCT06544460
- Testing
- Secondary cytoreduction, Hyperthermic intraperitoneal chemotherapy
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Fudan University
ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.
- Trial name
- CYCAD-1 (NCT06188520)
- Testing
- AZD8421, Camizestrant, Ribociclib
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Ovarian Cancer
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer.
- Trial name
- CORAIL (NCT02421588)
- Testing
- Lurbinectedin (PM01183), Pegylated liposomal doxorubicin (PLD), Topotecan
- Where
- 28 sites in United States
- Volunteers
- 442 people
- Sponsor
- PharmaMar
Breast Diseases, Polycystic Ovary
Breast Ultrasonography and Polycystic Ovary Syndrome
The results of the evaluation of breast ultrasonography results of patients with polycystic ovary syndrome diagnosis over 30 years of age will be evaluated.
- Trial name
- NCT04231786
- Testing
- Breast ultrasonography findings
- Where
- Turkey (Türkiye)
- Volunteers
- 1 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Ovarian Cancer, Breast Cancer
Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic…
- Trial name
- SOLI (NCT04330040)
- Testing
- Olaparib
- Where
- 16 sites in India
- Volunteers
- 202 people
- Sponsor
- AstraZeneca
Gynecologic Cancer, Colorectal Cancer
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects…
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05292859
- Testing
- Neoantigen specific TCR-T cell drug product
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Ovarian Cancer
Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer
The purpose of this study is to study efficacy and the effects on quality of life in women with ovarian cancer treated with a weekly schedule of chemotherapy with carboplatin and paclitaxel compared to those treated with standard…
- Trial name
- MITO-7 (NCT00660842)
- Testing
- carboplatin, paclitaxel
- Where
- 28 sites in Italy
- Volunteers
- 800 people
- Sponsor
- National Cancer Institute, Naples
Ovarian Cancer, Ovarian Carcinoma
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer
- Trial name
- NCT03748186
- Testing
- STRO-002
- Where
- 27 sites in United States, Spain
- Volunteers
- 136 people
- Sponsor
- Sutro Biopharma, Inc.
Ovarian Neoplasms
The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
Clinicopathological data were collected from ovarian cancer patients treated with PARP inhibitors, with follow-up imaging conducted before and after treatment.
- Trial name
- NCT06242392
- Testing
- homologous recombination deficiency
- Volunteers
- 250 people
- Sponsor
- Fujian Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.